Kariya Pharmaceuticals

2:00 PM - 2:15 PM, Tuesday, June 4,2019 ・ SuS - Hall E, Booth 3971, Level 200
Pharmaceutical company developing disease modifying agents to treat neurodegenerative diseases, such as Parkinson's disease. The agent being developed is a co-agonist that has demonstrated neuroprotective effects during clinical proof-of-concept trials and will be advancing to human trials. Currently, no approved drugs modify the degenerative course of Parkinson's disease, and the hallmark side effects of this disease are also observed in Type II Diabetes, which indicates that this agent has therapeutic potential in multiple patient populations and is addressing unmet medical needs.
Speaker
photo
Co
Kariya Pharma